Nov. 6, 2014, 8:31 AM
- Aegerion Pharmaceuticals (NASDAQ:AEGR) acquires Myalept (metreleptin for injection) from AstraZeneca (NYSE:AZN) for $325M. The drug is indicated for the treatment of leptin deficiency in patients with generalized lipodystrophy. It is the first and only product approved in the U.S. to treat the disease.
- Myalept has Orphan Drug status in the U.S., European Union and Japan.
AEGR vs. ETF Alternatives
Other News & PR